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Linear regression analysis between the creatinine concentrations measured by the present HPLC method (y) and those measured by the alkaline picrate method (x) yielded a mean (SD) slope of 1.4 (0.02) and y-intercept of 0.50 (0.14) mmol/L (r ϭ 0.997) for the control samples and a slope of 1.49 (0.06) and y-intercept of Ϫ0.15 (0.59) mmol/L (r ϭ 0.981) for the patient samples. The results were also compared by plotting the difference for creatinine measurements (HPLC Ϫ Jaffe) vs the mean concentration (Fig. 1B) according to the method of Bland and Altman (3 ) . Analysis by the Jaffe method gave urinary creatinine concentrations that were lower than those measured by HPLC in the whole concentration range (0.2-33 mmol/L). Best agreement between the methods was observed at creatinine concentrations Ͻ3 mmol/L. The greatest disagreement between the HPLC and Jaffe methods was for analysis of the urine samples from the patients and for urinary creatinine concentrations Ͼ10 mmol/L (Fig. 1B) . In accordance with the statement of the clinical institution at which the urinary creatinine was measured, all urine samples were diluted with distilled water by the same factor: 1:5 (by volume). We believe that the discrepancies noted at higher creatinine concentrations are attributable to interfering compounds in the Jaffe method, in which the extent of interference increased with increasing concentration of the interfering compounds.
We measured creatinine in serum samples from 17 hospitalized patients in duplicate by the present HPLC method with detection at 236 nm. The serum creatinine concentrations were determined with a mean imprecision (SD) of 4.5 (3.6)% and ranged between 58 and 219 mol/L. In seven of these samples, creatinine was also measured by HPLC analysis with detection at 215 nm. The ratio (SD) of the respective creatinine concentrations measured at the two wavelengths (236 nm/215 nm) was 0.97 (0.09) with a CV of 9.3%. In these analyses, the ratio of the peak areas for creatinine at the two wavelengths (215 nm/236 nm) was 4.4 (0.4). This ratio agrees with that obtained for aqueous solutions of creatinine calibrators (see above). Thus, these findings suggest no interferences from coeluting substances in these serum samples.
The proposed HPLC method is simple, rapid, and suitable for the accurate measurement of creatinine in urine, plasma, and serum samples from healthy and severely diseased humans. It also offers the opportunity to analyze creatine in plasma or serum. The method's simplicity and streamlined sample treatment make it suitable for automated analysis of creatinine. Approximately 5% of breast cancers are considered as hereditary, and their development is associated with germline mutations of specific genes. The BRCA1 gene was isolated in 1994 (1 ) and is estimated to account for almost one-half of inherited breast cancers and threefourths of inherited breast/ovarian cancers. BRCA1 is a large gene containing 5592 nucleotides spread over ϳ100 000 bases of genomic DNA.
More than 1200 different mutations have been found in BRCA1 associated with breast or ovarian cancer (2, 3 ). Mutations, recurring or unique in distribution, are dispersed throughout the coding sequence. Recurring mutations are either international or national. Six mutations have been observed commonly (3 ): 185delAG, 5382insC, 300TϾG, 4446CϾT, 4184delTCAA, and 3875delGTCT. Other frequent mutations have been localized to specific countries: 5149delCTAA (4 ) and 3958delCTCAGinsAGGC (5 ) in France; 2804delAA in Holland (6, 7 ); 3960 CϾT in northern France, Belgium, and Holland (8 ); and 3600del11 in northeastern France (9 ) .
As no functional assays are available, detection of BRCA1 mutations must be carried out at the DNA level. Because the gene is large and the mutations are distributed throughout its length, systematic sequencing is certainly the "gold standard" method. However, this method is time-consuming and expensive.
We describe here a method (10 ), multiplex singlenucleotide primer extension (MSNPE) analysis, to simultaneously detect 11 international and regional recurring mutations.
The patients were treated at the Centre Oscar Lambret for breast and/or ovarian cancer and belonged to highrisk families. Written informed consent was obtained from each patient. Genomic DNA was extracted from 2 mL of citrate blood samples by use of the QIAamp DNA Blood Midi Kit (Qiagen).
Fragments of BRCA1 gene containing the 11 recurrent screened mutations were amplified by multiplex PCR.
Clinical Chemistry
The PCR mixture (total volume, 25 L) contained 15 mM Tris-HCl (pH 8.0), 50 mM KCl, 2 mM MgCl 2 , 0.4 mM each of the deoxynucleotide triphosphates (Amersham Biosciences), 100 ng of genomic DNA, 2 U of AmpliTaq Gold DNA Polymerase (Applied Biosystems), and the primers (see Table 1 in the online Data Supplement that accompanies the online version of this Technical Brief at http:// www.clinchem.org/content/vol50/issue1/) at 1.6 M for exon 17, 0.8 M for exons 2 and 13, 0.4 M for exons 5 and 11H, 0.2 M for exon 11F, and 0.12 M for exon 20. After activation of AmpliTaq Gold DNA polymerase for 10 min at 95°C, the thermocycling conditions were 55 cycles at 94°C for 30 s, 54°C for 20 s, and 72°C for 2 min, with a final elongation step at 72°C for 8 min.
PCR products were purified by use of Sephacryl 400 (Amersham Biosciences) in Costar microplates and digested by incubation for 1 h at 37°C with exonuclease I (Amersham Biosciences) and shrimp alkaline phosphatase (Roche Diagnostics).
The MSNPE reaction was performed with the ABI Prism SnaPshot Multiplex reagent set (Applied Biosystems). The 11 purified primers (Genosys; Table 1), each specific for a screened mutation, bind to the complementary sequence in the presence of fluorescently labeled dideoxynucleotide triphosphates (ddNTPs), and the AmpliTaq DNA Polymerase extends the primer by adding a single ddNTP to its 3Ј end. Fluorescent dyes are assigned to the individual ddNTPs as follows: green for A, yellow for C (which for convenience is black on the electropherogram), blue for G, and red for T. The reaction mixture contained 3 L of PCR products, 5 L of multiplex reaction premixture (fluorescently labeled ddNTPs, AmpliTaq DNA polymerase, and reaction buffer), and 2 L of primers (0.5 pmol for mutation 3875delGTCT; 5 pmol for 185delAG, 300TϾC, 2804delAA, 3600del11, 3960CϾT, 4446CϾT, and 5382insC; and 10 pmol for the others). The reaction was performed as follows: 27 cycles at 96°C for 10 s, 50°C for 5 s, and 60°C for 30 s.
Samples were treated with 1 U of shrimp alkaline phosphatase at 37°C for 1 h, then diluted 10-fold with deionized formamide and denatured at 95°C for 5 min. The fluorescently labeled fragments were resolved by capillary electrophoresis on an automated ABI Prism 310 Genetic Analyzer (Applied Biosystems).
The specificity of the multiplex PCR was checked by electrophoresis of the products on 4% agarose gels containing ethidium bromide (see Fig. 1 in the online Data Supplement).
The MSNPE reaction was performed on samples previously analyzed by direct sequencing. All mutations were easily detected. Fig. 1 shows the electropherograms of the wild-type DNA and the three most frequent BRCA1 mutations (3 ) . Because all of the BRCA1 samples with mutated DNA were in a heterozygous state, two peaks were detected.
It is noteworthy that these two peaks did not overlap, although the sizes of their products were similar. This is a consequence of the electrophoretic mobility of these small final extension products, which depends not only on their lengths, but also on their nucleotide sequences and on the fluorescent dye used in the reaction.
To validate the procedure, we analyzed 48 DNA samples (24 samples with a BRCA1 mutation and 24 without). All of the mutations were always detected, and no falsepositive results were observed in samples without mutations, demonstrating the reliability of the procedure. Repetitive analyses demonstrated the reproducibility of the procedure.
The present procedure was accurate: All 48 DNA samples already genotyped by direct DNA sequencing displayed concordant results. The 11 heterozygous mutations were easily detected when compared with the wild-type profile. The criteria of specificity for a "mutant" peak were as follows: (a) a peak was observed with the expected size and color; (b) the obtained peak was at least threefold higher than the background peaks of the same color; and (c) the wild-type peak was decreased.
For each screened mutation, the primer was designed to anneal immediately adjacent to the nucleotide at the mutation site, on either the sense or antisense DNA strand. The primer orientation allowed multiplex PCR in the absence of intra-and intercomplementarity. Despite The wild-type DNA and the three most common mutations are shown. For each mutation, the two peaks in color correspond to the wild type and the mutated alleles.
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The present procedure allowed the detection of 36% of the cases identified in our region and 32% of the international mutations (3 ) . It could also be adapted easily and quickly by other laboratories to take into account their local mutation frequencies. In this regard, this procedure could potentially be a useful tool for prescreening studies.
The MSNPE reaction developed here requires only one reaction per patient sample, and it is possible to analyze 96 DNA samples in 1.5 working days. The subsequent interpretation of peak patterns is simple. This method is sensitive, rapid, and offers reduced laboratory costs. The multiplex technique increases both the practicability and ease of handling in the laboratory. If multichannel capillary electrophoresis instruments are used, this procedure could also be automated for high-throughput genotyping. Finally, a similar strategy can easily be developed to detect the most frequent BRCA2 mutations.
